Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
23
EVO Quote, Financials, Valuation and Earnings
Last price:
$3.1200
Seasonality move
:
5689.93%
Day range:
$3.0300 - $3.1400
52-week range:
$2.8400 - $5.1000
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.34x
P/B ratio:
1.18x
Volume:
35.4K
Avg. volume:
208.5K
1-year change:
-37.4%
Market cap:
$1.1B
Revenue:
$862.1M
EPS (TTM):
-$0.50
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EVO
Evotec SE
|
$219.8M | -$0.01 | 17.8% | -75.1% | $5.4436 |
|
BMY
Bristol Myers Squibb Co.
|
$11.8B | $1.52 | -0.85% | 4631.67% | $55.09 |
|
BNTX
BioNTech SE
|
$1.2B | $0.12 | -24.04% | -86.85% | $138.33 |
|
CVAC
CureVac NV
|
$25.1M | -$0.08 | 0.04% | -32.36% | $5.31 |
|
IFRX
InflaRx NV
|
$34.6K | -$0.14 | -74.55% | -16.09% | $11.24 |
|
IMTX
Immatics NV
|
$12.5M | -$0.45 | -81.87% | -704.25% | $18.75 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EVO
Evotec SE
|
$3.1300 | $5.4436 | $1.1B | -- | $0.00 | 0% | 1.34x |
|
BMY
Bristol Myers Squibb Co.
|
$54.69 | $55.09 | $111.3B | 18.47x | $0.62 | 4.54% | 2.32x |
|
BNTX
BioNTech SE
|
$95.13 | $138.33 | $22.9B | 191.55x | $0.00 | 0% | 6.47x |
|
CVAC
CureVac NV
|
$4.31 | $5.31 | $970.5M | 6.03x | $0.00 | 0% | 11.97x |
|
IFRX
InflaRx NV
|
$1.14 | $11.24 | $77.2M | -- | $0.00 | 0% | 352.24x |
|
IMTX
Immatics NV
|
$10.37 | $18.75 | $1.3B | 42.21x | $0.00 | 0% | 13.85x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EVO
Evotec SE
|
37.72% | 1.505 | 44.12% | 1.05x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.073 | 56.92% | 0.94x |
|
BNTX
BioNTech SE
|
1.31% | 1.267 | 1.22% | 6.78x |
|
CVAC
CureVac NV
|
3.87% | 1.835 | 3.39% | 1.84x |
|
IFRX
InflaRx NV
|
2.1% | -0.453 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.023 | 1.86% | 6.97x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EVO
Evotec SE
|
-$72.4K | -$59.7M | -11.62% | -17.7% | -31.17% | -$101.3M |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
CVAC
CureVac NV
|
$57.9M | -$11.6M | 19.52% | 20.55% | -18.33% | $31.6M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
Evotec SE vs. Competitors
-
Which has Higher Returns EVO or BMY?
Bristol Myers Squibb Co. has a net margin of -26.29% compared to Evotec SE's net margin of 17.96%. Evotec SE's return on equity of -17.7% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital EVOEvotec SE-0.04% -$0.14 $1.5B BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About EVO or BMY?
Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 74.58%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $55.09 which suggests that it could grow by 0.41%. Given that Evotec SE has higher upside potential than Bristol Myers Squibb Co., analysts believe Evotec SE is more attractive than Bristol Myers Squibb Co..
Company Buy Ratings Hold Ratings Sell Ratings EVOEvotec SE1 0 0 BMYBristol Myers Squibb Co.4 18 1 -
Is EVO or BMY More Risky?
Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.363%.
-
Which is a Better Dividend Stock EVO or BMY?
Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.54% to investors and pays a quarterly dividend of $0.62 per share. Evotec SE pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios EVO or BMY?
Evotec SE quarterly revenues are $191.5M, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Evotec SE's net income of -$50.3M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Evotec SE's price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.34x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVOEvotec SE1.34x -- $191.5M -$50.3M BMYBristol Myers Squibb Co.2.32x 18.47x $12.2B $2.2B
-
Which has Higher Returns EVO or BNTX?
BioNTech SE has a net margin of -26.29% compared to Evotec SE's net margin of -1.89%. Evotec SE's return on equity of -17.7% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital EVOEvotec SE-0.04% -$0.14 $1.5B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About EVO or BNTX?
Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 74.58%. On the other hand BioNTech SE has an analysts' consensus of $138.33 which suggests that it could grow by 46.94%. Given that Evotec SE has higher upside potential than BioNTech SE, analysts believe Evotec SE is more attractive than BioNTech SE.
Company Buy Ratings Hold Ratings Sell Ratings EVOEvotec SE1 0 0 BNTXBioNTech SE14 5 0 -
Is EVO or BNTX More Risky?
Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison BioNTech SE has a beta of 1.295, suggesting its more volatile than the S&P 500 by 29.477%.
-
Which is a Better Dividend Stock EVO or BNTX?
Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVO or BNTX?
Evotec SE quarterly revenues are $191.5M, which are smaller than BioNTech SE quarterly revenues of $1.8B. Evotec SE's net income of -$50.3M is lower than BioNTech SE's net income of -$33.5M. Notably, Evotec SE's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.34x versus 6.47x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVOEvotec SE1.34x -- $191.5M -$50.3M BNTXBioNTech SE6.47x 191.55x $1.8B -$33.5M
-
Which has Higher Returns EVO or CVAC?
CureVac NV has a net margin of -26.29% compared to Evotec SE's net margin of -5832.47%. Evotec SE's return on equity of -17.7% beat CureVac NV's return on equity of 20.55%.
Company Gross Margin Earnings Per Share Invested Capital EVOEvotec SE-0.04% -$0.14 $1.5B CVACCureVac NV91.57% $1.41 $1.1B -
What do Analysts Say About EVO or CVAC?
Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 74.58%. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 23.51%. Given that Evotec SE has higher upside potential than CureVac NV, analysts believe Evotec SE is more attractive than CureVac NV.
Company Buy Ratings Hold Ratings Sell Ratings EVOEvotec SE1 0 0 CVACCureVac NV1 3 0 -
Is EVO or CVAC More Risky?
Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.
-
Which is a Better Dividend Stock EVO or CVAC?
Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVO or CVAC?
Evotec SE quarterly revenues are $191.5M, which are larger than CureVac NV quarterly revenues of $63.3M. Evotec SE's net income of -$50.3M is lower than CureVac NV's net income of $319.3M. Notably, Evotec SE's price-to-earnings ratio is -- while CureVac NV's PE ratio is 6.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.34x versus 11.97x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVOEvotec SE1.34x -- $191.5M -$50.3M CVACCureVac NV11.97x 6.03x $63.3M $319.3M
-
Which has Higher Returns EVO or IFRX?
InflaRx NV has a net margin of -26.29% compared to Evotec SE's net margin of -51538.49%. Evotec SE's return on equity of -17.7% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital EVOEvotec SE-0.04% -$0.14 $1.5B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About EVO or IFRX?
Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 74.58%. On the other hand InflaRx NV has an analysts' consensus of $11.24 which suggests that it could grow by 886.3%. Given that InflaRx NV has higher upside potential than Evotec SE, analysts believe InflaRx NV is more attractive than Evotec SE.
Company Buy Ratings Hold Ratings Sell Ratings EVOEvotec SE1 0 0 IFRXInflaRx NV5 2 0 -
Is EVO or IFRX More Risky?
Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.
-
Which is a Better Dividend Stock EVO or IFRX?
Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVO or IFRX?
Evotec SE quarterly revenues are $191.5M, which are larger than InflaRx NV quarterly revenues of $27.8K. Evotec SE's net income of -$50.3M is lower than InflaRx NV's net income of -$14.3M. Notably, Evotec SE's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.34x versus 352.24x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVOEvotec SE1.34x -- $191.5M -$50.3M IFRXInflaRx NV352.24x -- $27.8K -$14.3M
-
Which has Higher Returns EVO or IMTX?
Immatics NV has a net margin of -26.29% compared to Evotec SE's net margin of -974.45%. Evotec SE's return on equity of -17.7% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital EVOEvotec SE-0.04% -$0.14 $1.5B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About EVO or IMTX?
Evotec SE has a consensus price target of $5.4436, signalling upside risk potential of 74.58%. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 80.81%. Given that Immatics NV has higher upside potential than Evotec SE, analysts believe Immatics NV is more attractive than Evotec SE.
Company Buy Ratings Hold Ratings Sell Ratings EVOEvotec SE1 0 0 IMTXImmatics NV9 0 0 -
Is EVO or IMTX More Risky?
Evotec SE has a beta of 1.821, which suggesting that the stock is 82.079% more volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.
-
Which is a Better Dividend Stock EVO or IMTX?
Evotec SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evotec SE pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVO or IMTX?
Evotec SE quarterly revenues are $191.5M, which are larger than Immatics NV quarterly revenues of $6.1M. Evotec SE's net income of -$50.3M is higher than Immatics NV's net income of -$59.1M. Notably, Evotec SE's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evotec SE is 1.34x versus 13.85x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVOEvotec SE1.34x -- $191.5M -$50.3M IMTXImmatics NV13.85x 42.21x $6.1M -$59.1M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
